^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PIK3CA wild-type + KRAS wild-type

    i
    Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K, KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845; 5290
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    1year
    Robust and cost effective in-vivo CAM models for drug combination study in colorectal cancer during COVID-19 pandemic (ESMO-GI 2023)
    The embryo of the chicken develops over 21 days and the CAM forms on day 3 to day 4 and serve as a respiratory organ with a rapidly developing vascular system. The CAM assay was performed using four cell lines DLD1 (KRAS/PIK3CA mutated) CACO2 (KRAS/PIK3CA wild-type), LS1034 (KRAS mutated) and SNUC4 (PIK3CA mutated) to demonstrate the anti-tumour effects of Ribociclib (R), Alpelisib (A), the combination of Ribociclib and Alpelisib (R+A) or DMSO as matched vehicle control (VC). The CAM assay is a robust and cost effective in-vivo model. We noted significant both macroscopic and microscopic evidence of best response with the R and A combination as compared to those treated with single agent drugs or DMSO vehicle control was in the CAM xenografts. These findings provide novel insight into a possible therapeutic strategy for patients with relapsed refractory CRC.
    Preclinical • HEOR • Cost-effectiveness • Cost effectiveness
    |
    KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    KRAS mutation • PIK3CA mutation • KRAS wild-type • PIK3CA wild-type • PIK3CA wild-type + KRAS wild-type
    |
    Piqray (alpelisib) • Kisqali (ribociclib)